Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT01211457 is registered in ClinicalTrials.gov with Cyclacel Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01211457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01211457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia or Myelodysplastic Syndromes
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 17, 2010
Completion date
December 31, 2020
Enrollment
65 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndromes